0001776985-26-000017 | 20-F | XBRL Viewer

Other Non-Financial Assets - Additional Information (Details) - EUR (€) € in Millions	Dec. 31, 2025	Dec. 31, 2024
Disclosure Of Income And Expenses [Line Items]
Deferred expenses	€ 8.4	€ 17.7

Label

Element

Value

Non-current Lease Liabilities, Loans And Borrowings

bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings

€ 215,200,000

Non-current Lease Liabilities, Loans And Borrowings

bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings

214,700,000

Current Lease Liabilities, Loans And Borrowings

bntx_CurrentLeaseLiabilitiesLoansAndBorrowings

52,200,000

Current Lease Liabilities, Loans And Borrowings

bntx_CurrentLeaseLiabilitiesLoansAndBorrowings

39,500,000

Treasury Shares Used For Acquisition Of Business Combination

bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination

Treasury Shares Used For Acquisition Of Business Combination

bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination

102,600,000

Treasury Shares Used For Acquisition Of Business Combination

bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination

1,100,000

Treasury Shares Used For Acquisition Of Business Combination

bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination

103,700,000

Share Repurchase Program, Repurchased During Period, Value

bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue

731,600,000

Share Repurchase Program, Repurchased During Period, Value

bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue

6,900,000

Share Repurchase Program, Repurchased During Period, Value

bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue

738,500,000

Current And Deferred Tax Expense (Income)

bntx_CurrentAndDeferredTaxExpenseIncome

104,800,000

Current And Deferred Tax Expense (Income)

bntx_CurrentAndDeferredTaxExpenseIncome

104,800,000

Issuance Of Share Capital

bntx_IssuanceOfShareCapital

10,400,000

Issuance Of Share Capital

bntx_IssuanceOfShareCapital

856,000,000.0

Issuance Of Share Capital

bntx_IssuanceOfShareCapital

866,400,000

Equity To Be Issued

bntx_EquityToBeIssued

132,600,000

Equity To Be Issued

bntx_EquityToBeIssued

132,600,000

Adjustments For Movements In Government Grants

bntx_AdjustmentsForMovementsInGovernmentGrants

(63,000,000.0)

Adjustments For Movements In Government Grants

bntx_AdjustmentsForMovementsInGovernmentGrants

(31,500,000)

Adjustments For Movements In Government Grants

bntx_AdjustmentsForMovementsInGovernmentGrants

2,400,000

Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets

bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets

1,083,700,000

Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets

bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets

387,700,000

Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets

bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets

5,374,000,000

Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions

bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions

(723,800,000)

Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions

bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions

758,400,000

Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions

bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions

118,900,000

Share based Payments, Classified As Operating Activities

bntx_ShareBasedPaymentsClassifiedAsOperatingActivities

(25,300,000)

Share based Payments, Classified As Operating Activities

bntx_ShareBasedPaymentsClassifiedAsOperatingActivities

(154,500,000)

Share based Payments, Classified As Operating Activities

bntx_ShareBasedPaymentsClassifiedAsOperatingActivities

(766,200,000)

Government Grants Received

bntx_GovernmentGrantsReceived

75,100,000

Government Grants Received

bntx_GovernmentGrantsReceived

106,000,000.0

Government Grants Received

bntx_GovernmentGrantsReceived

Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities

bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities

4,500,000

Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities

bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities

1,200,000

Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities

bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities

(700,000)

Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities

bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities

573,900,000

Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities

bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities

165,800,000

Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities

bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities

455,400,000

(Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities

bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities

9,512,200,000

(Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities

bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities

10,740,200,000

(Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities

bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities

1,216,300,000

Share Repurchase Program Classified As Financing Activities

bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities

Share Repurchase Program Classified As Financing Activities

bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities

Share Repurchase Program Classified As Financing Activities

bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities

738,500,000

Effect Of Other Valuation Changes On Cash And Cash Equivalents

bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents

5,900,000

Effect Of Other Valuation Changes On Cash And Cash Equivalents

bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents

2,800,000

Effect Of Other Valuation Changes On Cash And Cash Equivalents

bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents

€ 164,800,000

Useful Life Measured As Period Of Time, Right-Of-Use Assets

bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets

2 years

Useful Life Measured As Period Of Time, Right-Of-Use Assets

bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets

25 years

Useful Life Measured As Period Of Time, Right-Of-Use Assets

bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets

2 years

Useful Life Measured As Period Of Time, Right-Of-Use Assets

bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets

5 years

Useful Life Measured As Period Of Time, Right-Of-Use Assets

bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets

2 years

Useful Life Measured As Period Of Time, Right-Of-Use Assets

bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets

3 years

Useful Life Measured As Period Of Time, Right-Of-Use Assets

bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets

3 years

Useful Life Measured As Period Of Time, Right-Of-Use Assets

bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets

4 years

Other Assets Non-current And Current Recognised As Of Acquisition Date

bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate

€ 20,600,000

Other Assets Non-current And Current Recognised As Of Acquisition Date

bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate

26,300,000

Assets Recognised As Of Acquisition Date

bntx_AssetsRecognisedAsOfAcquisitionDate

386,500,000

Assets Recognised As Of Acquisition Date

bntx_AssetsRecognisedAsOfAcquisitionDate

647,400,000

Liabilities Recognised As Of Acquisition Date

bntx_LiabilitiesRecognisedAsOfAcquisitionDate

91,400,000

Liabilities Recognised As Of Acquisition Date

bntx_LiabilitiesRecognisedAsOfAcquisitionDate

257,100,000

Bargain From The Acquisition, Acquisition-Date Fair Value

bntx_BargainFromTheAcquisitionAcquisitionDateFairValue

15,000,000.0

Purchase Price, Acquisition-Date Fair Value

bntx_PurchasePriceAcquisitionDateFairValue

847,400,000

Purchase Price, Acquisition-Date Fair Value

bntx_PurchasePriceAcquisitionDateFairValue

1,001,100,000

Previously-held Non-listed Equity Investment

bntx_PreviouslyHeldNonListedEquityInvestment

567,300,000

Previously-held Non-listed Equity Investment

bntx_PreviouslyHeldNonListedEquityInvestment

600,300,000

Equity-Settled Share-Based Payment Transactions, Fair Value At Grant Date

bntx_EquitySettledShareBasedPaymentTransactionsFairValueAtGrantDate

€ 49,200,000

Vesting Period Of Share-Based Payment Arrangement

bntx_VestingPeriodOfShareBasedPaymentArrangement

4 years

Settlement of pre-existing relationships

bntx_SettlementOfPreExistingRelationships

€ 565,100,000

Purchase Price, Acquisition-Date Fair Value, First and Second Offering Period

bntx_PurchasePriceAcquisitionDateFairValueFirstAndSecondOfferingPeriod

868,400,000

Purchase Price, Acquisition-Date Fair Value, Back-End Measures

bntx_PurchasePriceAcquisitionDateFairValueBackEndMeasures

€ 132,700,000

Exchange Ratio In Business Combination

bntx_ExchangeRatioInBusinessCombination

0.05363

Exchange Rate Used To Determine Fair Value In Business Combination

bntx_ExchangeRateUsedToDetermineFairValueInBusinessCombination

0.86

Settlement Of Contractual Pre-Existing Relationships

bntx_SettlementOfContractualPreExistingRelationships

€ 488,900,000

Settlement Of Non-Contractual Pre-Existing Relationships

bntx_SettlementOfNonContractualPreExistingRelationships

111,400,000

Issue Costs Of Equity Instruments For Business Combination

bntx_IssueCostsOfEquityInstrumentsForBusinessCombination

2,000,000.0

Expected Revenues From Remaining Performance Obligations

bntx_ExpectedRevenuesFromRemainingPerformanceObligations

2,000,000,000.0

Contingent Revenues From Remaining Performance Obligations

bntx_ContingentRevenuesFromRemainingPerformanceObligations

7,600,000,000

Remaining Upfront Fees Contract Liabilities

bntx_RemainingUpfrontFeesContractLiabilities

1,100,000

Remaining Upfront Fees Contract Liabilities

bntx_RemainingUpfrontFeesContractLiabilities

€ 61,100,000

Disclosure Of Income And Expense Explanatory [Text Block]

bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock

Income and Expenses7.1 General Expenses

Cost of Sales

Our cost of sales increased by €100.5 million, or 19%, from €541.3 million during the year ended December 31,

2024 to €641.8 million during the year ended December 31, 2025. This increase was mainly driven by higher

COVID-19 vaccine sales in our commercialization territory, which included the share of gross profit we owe our

collaboration partner Pfizer, higher expenses from inventory scrapping and write-downs to net realizable value

and impairments on property, plant and equipment from the analysis on CGU External Product Sales JPT of

€30.5 million. Expenses arising from inventory write-downs to net realizable value amounted to €162.8 million

during the year ended December 31, 2025 compared to €125.8 million for year ended December 31, 2024

(€94.5 million for year ended December 31, 2023). In addition, our cost of sales during the fiscal year 2024 have

been impacted by multiple positive extraordinary effects, including from inventory valuation effects.

Comparing the years ended December 31, 2024 and 2023, our cost of sales decreased by €58.5 million, or 10%,

from €599.8 million to €541.3 million. This change is mainly due to recognizing lower cost of sales from our

decreased COVID-19 vaccine sales, which included the share of gross profit we owe our collaboration partner

Pfizer based on our sales.

Research and Development Expenses

Our research and development expenses decreased by €149.3 million, or 7%, from €2,254.2 million during the

year ended December 31, 2024 to €2,104.9 million during the year ended December 31, 2025. This

development was mainly driven by cost savings resulting from active portfolio management and positive effects

resulting from our cost share with our collaboration partner BMS, partly offset by the acceleration of late-stage

trials for our immuno-oncology, or IO, and antibody-drug conjugate, or ADC, programs and by an impairment of

Trastuzumab Pamirtecan (BNT323/DB-1303) of €85.4 million (see Note 10).

Comparing the years ended December 31, 2024 and 2023, our research and development expenses increased

by €471.1 million, or 26%, from €1,783.1 million to €2,254.2 million, mainly driven by advancing key pipeline

candidates, such as our ADC and IO programs and from higher personnel expenses resulting from an increase

in headcount.

Sales and Marketing Expenses

Our sales and marketing expenses increased by €42.1 million, or 62%, from €67.9 million during the year ended

December 31, 2024 to €110.0 million during the year ended December 31, 2025, mainly due to our ongoing

commercial build-up.

Comparing the years ended December 31, 2024 and 2023, our sales and marketing expenses increased by €5.2

million, or 8%, from €62.7 million to €67.9 million, mainly due to increased expenses for setup and enhancement

of commercial IT platforms and an increase in personnel expenses resulting from an increase in headcount.

General and Administrative Expenses

Our general and administrative expenses decreased by €16.7 million, or 3%, from €531.1 million during the year

ended December 31, 2024 to €514.4 million during the year ended December 31, 2025. The decrease was

primarily driven by a reduction in external services and our continued cost discipline.

Comparing the years ended December 31, 2024 and 2023, our general and administrative expenses increased

by €36.1 million, or 7%, from €495.0 million to €531.1 million, mainly influenced by increased expenses for IT

services as well as by an increase in personnel expenses resulting from an increase in headcount.

7.2 Other Operating Result



	Years ended December 31,

(in millions €)	2025	2024	2023
Other operating income	184.6	140.6	105.0
Gain on derivative instruments at fair value through profit or loss	65.1	—	67.6
Government and similar grants	63.0	31.5	2.2
Bargain purchase	15.0	—	—
Foreign exchange differences, net	—	84.9	—
Other	41.5	24.2	35.2
Other operating expenses	(1,088.3)	(811.5)	(293.0)
Contractual disputes / settlements	(789.5)	(657.4)	—
Pipeline prioritization costs	(148.3)	—	—
External legal advice services	(73.8)	(113.7)	(29.4)
Loss on derivative instruments at fair value through profit or loss	—	(32.4)	—
Foreign exchange differences, net	(48.9)	—	(252.0)
Impairment losses and reversals of impairment losses on financial assets (operating result), net	(5.9)	—	(0.8)
Other	(21.9)	(8.0)	(10.8)
Total other operating result	(903.7)	(670.9)	(188.0)

Our total other operating result decreased by €232.8 million, or 35%, from a negative operating result of €670.9

million during the year ended December 31, 2024 to a negative operating result of €903.7 million during the year

ended December 31, 2025. Our expenses in connection with our pipeline prioritization included impairments of

€71.6 million and employee-related costs of €57.0 million. The impairments comprise €57.8 million on property,

plant and equipment (see Note 11) and €13.8 million on right-of-use assets (see Note 20), all located outside of

Europe. For more information regarding the nature of the government and similar grants, please see Note 19.

As for 2024 and 2023, our total other operating result decreased by €482.9 million, or 257%, from a negative

operating result of €188.0 million during the year ended December 31, 2023 to a negative operating result of

€670.9 million during the year ended December 31, 2024. The change was mainly due to the settlement of

contractual disputes and related expenses to such disputes and other litigations7.3 Finance Result



	Years ended December 31,

(in millions €)	2025	2024	2023
Total finance income	423.9	664.0	519.6
Interest income from effective interest method	262.6	437.6	330.9
Other gains	161.3	210.9	188.7
Gains from financial assets or financial liabilities that are mandatorily measured at fair value through profit or loss	158.2	210.9	162.0
Other gains from financial assets subsequently measured at amortized cost	3.1	—	26.7
Foreign exchange differences, net	—	15.5	—
Total finance expenses	(69.8)	(27.4)	(23.9)
Foreign exchange differences, net	(48.4)	—	(15.9)
Interest expenses from effective interest method and other interest expenses	(14.2)	(16.9)	(7.5)
Other losses	(7.2)	(10.5)	(0.5)
Impairment losses on financial assets	(0.5)	(4.2)	—
Losses from financial assets or financial liabilities that are mandatorily measured at fair value through profit or loss	(5.2)	(6.0)	(0.5)
Fee expense from financial assets and financial liabilities that are not subsequently measured at fair value through profit or loss	(1.5)	(0.3)	—
Total finance result	354.1	636.6	495.7

Our finance result during the years ended December 31, 2025, 2024 and 2023 was mainly derived from returns,

such as interest, resulting from our financial investments as well as fair value adjustments of our money market

funds. Our total finance result decreased by €282.5 million, or 44%, from a positive finance result of €636.6

million during the year ended December 31, 2024 to a positive finance result of €354.1 million during the year

ended December 31, 2025. This change was mainly due to lower interest income and negative impacts from

foreign exchange differences, primarily derived from our security investments disclosed as cash equivalents and

bank accounts held in foreign currency.

Our total finance result increased by €140.9 million, or 28%, from a positive finance result of €495.7 million

during the December 31, 2023 to a positive finance result of €636.6 million during the year ended December 31,

2024. This change was mainly due to higher interest income and positive foreign exchange differences, primarily

derived from our security investments disclosed as cash equivalents and bank cash accounts held in foreign

currency.

7.4 Employee Benefits Expense



	Years ended December 31,

(in millions €)	2025	2024	2023
Wages and salaries	915.0	814.0	617.8
Social security costs	110.0	113.7	76.7
Pension costs	4.7	3.5	4.1
Total	1,029.7	931.2	698.6

Wages and salaries include, among other things, expenses for share-based and severance payments. The

increase between the year ended December 31, 2024 and 2025 primarily reflects the inclusion of the workforce

from the acquisition of Biotheus in 2025 (see Note 5), increased base salaries and severance payments related

to our ongoing transformation.

Comparing the years ended December 31, 2024 and 2023, the development is mainly due to changes in

headcount between the respective years

Increase (Decrease) Cost Of Sales

bntx_IncreaseDecreaseCostOfSales

€ 100,500,000

Increase (Decrease) Cost Of Sales

bntx_IncreaseDecreaseCostOfSales

€ (58,500,000)

Percentage Of Cost Of Sales

bntx_PercentageOfCostOfSales

19.00%

Percentage Of Cost Of Sales

bntx_PercentageOfCostOfSales

(10.00%)

Increase (Decrease) Of Research And Development Expense

bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense

€ (149,300,000)

Increase (Decrease) Of Research And Development Expense

bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense

€ 471,100,000

Percentage Of Research And Development Expense

bntx_PercentageOfResearchAndDevelopmentExpense

(7.00%)

Percentage Of Research And Development Expense

bntx_PercentageOfResearchAndDevelopmentExpense

26.00%

Increase (Decrease) Of Sales And Marketing Expense

bntx_IncreaseDecreaseOfSalesAndMarketingExpense

€ 42,100,000

Increase (Decrease) Of Sales And Marketing Expense

bntx_IncreaseDecreaseOfSalesAndMarketingExpense

€ 5,200,000

Percentage Of Sales And Marketing Expense

bntx_PercentageOfSalesAndMarketingExpense

62.00%

Percentage Of Sales And Marketing Expense

bntx_PercentageOfSalesAndMarketingExpense

8.00%

Increase (Decrease) Of General And Administrative Expense

bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense

€ (16,700,000)

Increase (Decrease) Of General And Administrative Expense

bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense

€ 36,100,000

Percentage Of General And Administrative Expense

bntx_PercentageOfGeneralAndAdministrativeExpense

(3.00%)

Percentage Of General And Administrative Expense

bntx_PercentageOfGeneralAndAdministrativeExpense

7.00%

Disclosure Of Other Operating Result [Table Text Block]

bntx_DisclosureOfOtherOperatingResultTableTextBlock



	Years ended December 31,

(in millions €)	2025	2024	2023
Other operating income	184.6	140.6	105.0
Gain on derivative instruments at fair value through profit or loss	65.1	—	67.6
Government and similar grants	63.0	31.5	2.2
Bargain purchase	15.0	—	—
Foreign exchange differences, net	—	84.9	—
Other	41.5	24.2	35.2
Other operating expenses	(1,088.3)	(811.5)	(293.0)
Contractual disputes / settlements	(789.5)	(657.4)	—
Pipeline prioritization costs	(148.3)	—	—
External legal advice services	(73.8)	(113.7)	(29.4)
Loss on derivative instruments at fair value through profit or loss	—	(32.4)	—
Foreign exchange differences, net	(48.9)	—	(252.0)
Impairment losses and reversals of impairment losses on financial assets (operating result), net	(5.9)	—	(0.8)
Other	(21.9)	(8.0)	(10.8)
Total other operating result	(903.7)	(670.9)	(188.0)

Increase (Decrease) In Other Operating Income (Expense)

bntx_IncreaseDecreaseInOtherOperatingIncomeExpense

€ (232,800,000)

Increase (Decrease) In Other Operating Income (Expense)

bntx_IncreaseDecreaseInOtherOperatingIncomeExpense

€ (482,900,000)

Percent Increase (Decrease) In Other Operating Income (Expense)

bntx_PercentIncreaseDecreaseInOtherOperatingIncomeExpense

0.35

Percent Increase (Decrease) In Other Operating Income (Expense)

bntx_PercentIncreaseDecreaseInOtherOperatingIncomeExpense

2.57

Disclosure Of Finance Income and Costs Explanatory [Table Text Block]

bntx_DisclosureOfFinanceIncomeAndCostsExplanatoryTableTextBlock



	Years ended December 31,

(in millions €)	2025	2024	2023
Total finance income	423.9	664.0	519.6
Interest income from effective interest method	262.6	437.6	330.9
Other gains	161.3	210.9	188.7
Gains from financial assets or financial liabilities that are mandatorily measured at fair value through profit or loss	158.2	210.9	162.0
Other gains from financial assets subsequently measured at amortized cost	3.1	—	26.7
Foreign exchange differences, net	—	15.5	—
Total finance expenses	(69.8)	(27.4)	(23.9)
Foreign exchange differences, net	(48.4)	—	(15.9)
Interest expenses from effective interest method and other interest expenses	(14.2)	(16.9)	(7.5)
Other losses	(7.2)	(10.5)	(0.5)
Impairment losses on financial assets	(0.5)	(4.2)	—
Losses from financial assets or financial liabilities that are mandatorily measured at fair value through profit or loss	(5.2)	(6.0)	(0.5)
Fee expense from financial assets and financial liabilities that are not subsequently measured at fair value through profit or loss	(1.5)	(0.3)	—
Total finance result	354.1	636.6	495.7

Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Fair Value

bntx_FinanceCostsFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue

€ 5,200,000

Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Fair Value

bntx_FinanceCostsFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue

6,000,000.0

Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Fair Value

bntx_FinanceCostsFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue

500,000

Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Amortized Cost Without Expected Credit Losses

bntx_FinanceCostsFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtAmortizedCostWithoutExpectedCreditLosses

1,500,000

Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Amortized Cost Without Expected Credit Losses

bntx_FinanceCostsFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtAmortizedCostWithoutExpectedCreditLosses

300,000

Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Amortized Cost Without Expected Credit Losses

bntx_FinanceCostsFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtAmortizedCostWithoutExpectedCreditLosses

Increase (Decrease) In Finance Income (Costs)

bntx_IncreaseDecreaseInFinanceIncomeCosts

(282,500,000)

Increase (Decrease) In Finance Income (Costs)

bntx_IncreaseDecreaseInFinanceIncomeCosts

€ 140,900,000

Finance Income (Costs), Percentage Change

bntx_FinanceIncomeCostsPercentageChange

(0.44)

Finance Income (Costs), Percentage Change

bntx_FinanceIncomeCostsPercentageChange

0.28

Disclosure Of Detailed Information About Employee Benefits Expense Explanatory [Table Text Block]

bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock



	Years ended December 31,

(in millions €)	2025	2024	2023
Wages and salaries	915.0	814.0	617.8
Social security costs	110.0	113.7	76.7
Pension costs	4.7	3.5	4.1
Total	1,029.7	931.2	698.6

Corporate Tax Rate

bntx_CorporateTaxRate

15.00%

Solidarity Surcharge Rate

bntx_SolidaritySurchargeRate

5.50%

Tax Effect Of Deviation Due To Local Tax Basis

bntx_TaxEffectOfDeviationDueToLocalTaxBasis

€ 11,900,000

Tax Effect Of Deviation Due To Local Tax Basis

bntx_TaxEffectOfDeviationDueToLocalTaxBasis

12,600,000

Tax Effect Of Deviation Due To Local Tax Basis

bntx_TaxEffectOfDeviationDueToLocalTaxBasis

6,600,000

Tax Effect Of Change In Valuation Allowance

bntx_TaxEffectOfChangeInValuationAllowance

68,300,000

Tax Effect Of Change In Valuation Allowance

bntx_TaxEffectOfChangeInValuationAllowance

(16,400,000)

Tax Effect Of Change In Valuation Allowance

bntx_TaxEffectOfChangeInValuationAllowance

(14,300,000)

Tax Effect Of Expense Not Deductible In Determining Taxable Profit (Tax Loss), Net Of Addiitonal Deductions

bntx_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNetOfAddiitonalDeductions

41,000,000.0

Tax Effect Of Expense Not Deductible In Determining Taxable Profit (Tax Loss), Net Of Addiitonal Deductions

bntx_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNetOfAddiitonalDeductions

(49,100,000)

Tax Effect Of Expense Not Deductible In Determining Taxable Profit (Tax Loss), Net Of Addiitonal Deductions

bntx_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNetOfAddiitonalDeductions

3,100,000

Tax Effect, Non Tax Effective Income

bntx_TaxEffectNonTaxEffectiveIncome

(5,000,000.0)

Tax Effect, Non Tax Effective Income

bntx_TaxEffectNonTaxEffectiveIncome

(2,100,000)

Tax Effect, Non Tax Effective Income

bntx_TaxEffectNonTaxEffectiveIncome

(600,000)

Non-Recognition Of Tax Effect On Share-Based Payment Expenses

bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses

(600,000)

Non-Recognition Of Tax Effect On Share-Based Payment Expenses

bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses

(37,200,000)

Non-Recognition Of Tax Effect On Share-Based Payment Expenses

bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses

7,700,000

Tax Effective Equity Transaction Costs

bntx_TaxEffectiveEquityTransactionCosts

(600,000)

Tax Effective Equity Transaction Costs

bntx_TaxEffectiveEquityTransactionCosts

Tax Effective Equity Transaction Costs

bntx_TaxEffectiveEquityTransactionCosts

Non Tax Effective Bargain Purchase

bntx_NonTaxEffectiveBargainPurchase

Non Tax Effective Bargain Purchase

bntx_NonTaxEffectiveBargainPurchase

Non Tax Effective Bargain Purchase

bntx_NonTaxEffectiveBargainPurchase

Deferred Tax Expense (Income) Recognised In Other Comprehensive Income